TABLE 4.

Inhibitory activities of the 14 lead compounds against the binding of VA387 to eight saliva samples from randomly selected type A individuals

Compound	Concn (μM) of compounda	% Inhibition of binding to saliva sample:								Avg % inhibition (mean ± SD)
		1	2	3	4	5	6	7	8
1	2.2	48.1	56.2	46.5	47.1	52.2	55.4	41.2	47.1	49.3 ± 5.0
2	4.8	60.1	61.7	66.2	64.3	67.6	65.5	60.2	63.3	61.1 ± 2.8
3	7.8	62.2	50.2	56.4	54.3	51.2	52.2	47.5	60.3	53.8 ± 5.1
4	8.1	58.1	56.5	65.1	64.3	58.7	62.3	57.5	61.4	59.3 ± 3.2
5	9.1	66.1	70.1	72.5	62.3	62.4	65.7	61.1	55.5	62.9 ± 5.4
6	9.3	61.2	51.0	52.3	49.3	48.1	54.6	54.7	63.2	53.8 ± 5.4
7	9.6	45.4	44.3	53.2	55.1	39.7	42.0	46.1	31.7	45.3 ± 7.4
8	10.9	38.3	42.5	49.6	60.3	50.1	44.9	52.4	52.7	49.0 ± 6.8
9	11.7	41.8	35.7	57.1	55.5	53.3	55.4	60.2	53.6	51.4 ± 8.4
10	11.8	55.7	40.8	58.2	55.9	44.3	59.5	56.2	37.6	50.9 ± 8.6
11	12.8	34.7	43.3	55.1	40.0	44.4	48.6	46.2	52.2	46.1 ± 6.5
12	12.8	43.2	53.4	60.3	54.9	55.4	64.2	57.3	49.8	54.3 ± 6.4
13	13.6	42.2	48.1	48.4	56.5	50.1	55.1	40.4	49.7	48.9 ± 5.6
14	13.7	54.3	51.3	62.4	51.4	41.3	50.5	55.2	43.7	51.1 ± 6.6

^aEC₅₀ obtained in the primary screening.